159 related articles for article (PubMed ID: 15621015)
1. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease.
Reynolds NC; Prost RW; Mark LP
Brain Res; 2005 Jan; 1031(1):82-9. PubMed ID: 15621015
[TBL] [Abstract][Full Text] [Related]
2. MR-spectroscopic findings in juvenile-onset Huntington's disease.
Reynolds NC; Prost RW; Mark LP; Joseph SA
Mov Disord; 2008 Oct; 23(13):1931-5. PubMed ID: 18759332
[TBL] [Abstract][Full Text] [Related]
3. 1H magnetic resonance spectroscopy in preclinical Huntington disease.
van Oostrom JC; Sijens PE; Roos RA; Leenders KL
Brain Res; 2007 Sep; 1168():67-71. PubMed ID: 17707354
[TBL] [Abstract][Full Text] [Related]
4. Is brain lactate increased in Huntington's disease?
Martin WR; Wieler M; Hanstock CC
J Neurol Sci; 2007 Dec; 263(1-2):70-4. PubMed ID: 17655868
[TBL] [Abstract][Full Text] [Related]
5. In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure.
Verma A; Saraswat VA; Radha Krishna Y; Nath K; Thomas MA; Gupta RK
Liver Int; 2008 Sep; 28(8):1095-103. PubMed ID: 18266634
[TBL] [Abstract][Full Text] [Related]
6. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory.
Taylor-Robinson SD; Weeks RA; Bryant DJ; Sargentoni J; Marcus CD; Harding AE; Brooks DJ
Mov Disord; 1996 Mar; 11(2):167-73. PubMed ID: 8684387
[TBL] [Abstract][Full Text] [Related]
7. Cerebral diffusion tensor imaging and in vivo proton magnetic resonance spectroscopy in patients with fulminant hepatic failure.
Saksena S; Rai V; Saraswat VA; Rathore RS; Purwar A; Kumar M; Thomas MA; Gupta RK
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e111-9. PubMed ID: 17924951
[TBL] [Abstract][Full Text] [Related]
8. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study.
Appenzeller S; Li LM; Costallat LT; Cendes F
Brain; 2005 Dec; 128(Pt 12):2933-40. PubMed ID: 16195241
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal metabolite changes in Huntington's disease during disease onset.
van den Bogaard SJ; Dumas EM; Teeuwisse WM; Kan HE; Webb A; van Buchem MA; Roos RA; van der Grond J
J Huntingtons Dis; 2014; 3(4):377-86. PubMed ID: 25575959
[TBL] [Abstract][Full Text] [Related]
10. 1H magnetic resonance spectroscopy at 3 T in cryptogenic and mesial temporal lobe epilepsy.
Riederer F; Bittsanský M; Schmidt C; Mlynárik V; Baumgartner C; Moser E; Serles W
NMR Biomed; 2006 Aug; 19(5):544-53. PubMed ID: 16521092
[TBL] [Abstract][Full Text] [Related]
11. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Wang Z; Zhao C; Yu L; Zhou W; Li K
Acta Radiol; 2009 Apr; 50(3):312-9. PubMed ID: 19235582
[TBL] [Abstract][Full Text] [Related]
12. Single voxel proton magnetic resonance spectroscopy in post-stroke depression.
Glodzik-Sobanska L; Slowik A; McHugh P; Sobiecka B; Kozub J; Rich KE; Urbanik A; Szczudlik A
Psychiatry Res; 2006 Dec; 148(2-3):111-20. PubMed ID: 17088051
[TBL] [Abstract][Full Text] [Related]
13. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.
Garcia M; Huppertz HJ; Ziyeh S; Buechert M; Schumacher M; Mader I
Epilepsia; 2009 Mar; 50(3):486-92. PubMed ID: 19183221
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy.
Lin K; Carrete H; Lin J; Peruchi MM; de Araújo Filho GM; Guaranha MS; Guilhoto LM; Sakamoto AC; Yacubian EM
Epilepsia; 2009 May; 50(5):1191-200. PubMed ID: 19220412
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
16. Reduced prefrontal N-acetylaspartate in stroke patients with apathy.
Glodzik-Sobanska L; Slowik A; Kieltyka A; Kozub J; Sobiecka B; Urbanik A; Szczudlik A
J Neurol Sci; 2005 Nov; 238(1-2):19-24. PubMed ID: 16084528
[TBL] [Abstract][Full Text] [Related]
17. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder.
Yücel M; Wood SJ; Wellard RM; Harrison BJ; Fornito A; Pujol J; Velakoulis D; Pantelis C
Aust N Z J Psychiatry; 2008 Jun; 42(6):467-77. PubMed ID: 18465373
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging.
Boesch SM; Wolf C; Seppi K; Felber S; Wenning GK; Schocke M
J Magn Reson Imaging; 2007 Mar; 25(3):564-9. PubMed ID: 17326083
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.
Sturrock A; Laule C; Wyper K; Milner RA; Decolongon J; Dar Santos R; Coleman AJ; Carter K; Creighton S; Bechtel N; Bohlen S; Reilmann R; Johnson HJ; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
Mov Disord; 2015 Mar; 30(3):393-401. PubMed ID: 25690257
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
